Zevra Therapeutics, Inc. (ZVRA) Misses Q2 EPS by 2c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q2 EPS of ($0.48), $0.02 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $4.41 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Science Applications Int'l (SAIC) Tops Q2 EPS by 70c
• TELA Bio to cut 20% of workforce, expects $1.5M in charges
• ONEOK (OKE) Reiterated at Neutral by UBS as Brazos Midstream Deal Agreement Announced